Get notified when INO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern due to insufficient working capital.
- Litigation (new) — The company faces a securities class action and derivative suits alleging false statements about its BLA submission and FDA review timeline.
INOVIO Pharmaceuticals files preliminary prospectus for common stock and warrant offering; terms not yet set
Filed July 29, 2026 · ~1 min read
Key Changes
-
high
INOVIO is offering common stock with accompanying warrants, but the number of shares, price, and proceeds are left blank in this preliminary prospectus supplement.
The Offering verify on EDGAR → -
high
The company has substantial doubt about its ability to continue as a going concern, with insufficient working capital for the next twelve months.
Prospectus Summary verify on EDGAR → -
high
Net proceeds are intended for preparing a potential commercial launch of INO-3107, a confirmatory trial, pipeline development, and general corporate purposes.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WLTH 10-Q) is open in full — no account needed.
Partner
Trade INO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify